Jo Hulme

Jo Hulme has a strong background in the biopharmaceutical industry, with extensive experience in research and development. Jo is currently serving as the Chief Scientific Officer at Radiant Biotherapeutics since May 2023, where they oversee scientific operations. Prior to this, they held the position of VP and Head of R&D at Radiant Biotherapeutics from January 2021 to May 2023.

Before joining Radiant Biotherapeutics, Jo Hulme worked at Northern Biologics from 2015 to 2021. Jo held various roles during their tenure, including VP and Head of Research from March 2019 to January 2021, Senior Director in Immuno-Oncology from April 2018 to May 2019, and Director from April 2015 to April 2018.

Jo Hulme's earlier career includes working at Amgen from 2006 to 2014. Jo held the position of Senior Scientist and was responsible for leading projects in novel bi-specific antibody programs and multi-functional research teams. Jo also developed novel platforms for discovery research. Prior to that, they worked as a Scientist at Amgen from 2006 to 2010, where they led a project in novel antibody-based program in Osteoarthritis and was involved in platform development and discovery projects.

Jo Hulme's academic experience includes roles at the University of Washington from 1999 to 2006. Jo served as an Acting Instructor from January 2003 to March 2006, leading a project on the autoinhibitory control of the cardiac calcium channel. Prior to that, they worked as a Post-doctoral Fellow from May 1999 to December 2002.

Jo Hulme pursued their undergraduate degree in Pharmacology from the University of Leeds, from 1991 to 1994. Jo then continued their education at the same institution, completing a Ph.D. from 1994 to 1998, focusing on Cardiac Muscle Research Group.